Whitehawk Therapeutics, Inc.
Clinical trials sponsored by Whitehawk Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing therapies for rare diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug HWK-016 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug HWK-007 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…
Phase: PHASE1 • Sponsor: Whitehawk Therapeutics, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC